Navigation Links
Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
Date:3/17/2008

Physician's office system for measuring airway inflammation poised to

transform asthma management for improved control.

MENLO PARK, Calif., March 17 /PRNewswire/ -- Apieron, Inc. (http://www.apieron.com) announced today that the Insight eNO system has received clearance to market by the U.S. Food and Drug Administration.

The Insight eNO system measures exhaled nitric oxide (eNO), which is a well-established indicator of airway inflammation and asthma control. The Insight system is a highly accurate device, expressly designed for the physician's office. It is non-invasive, safe, easy to use, and provides results in less than a minute. Apieron's unique biosensor detects trace amounts of nitric oxide molecules in a single human breath utilizing a proprietary technology. Current methods and techniques used to diagnose, monitor and treat asthma are costly, time-consuming and cumbersome. Physician office measurement of eNO is a much-awaited breakthrough in medical technology that provides physicians with a reliable tool to measure their patients' respiratory inflammation better than ever before. Measurement of eNO has also been shown to optimize medication therapy and improve compliance among patients with asthma.

William Berger, M.D., Clinical Professor of Pediatrics, University of California, Irvine, and Mission Viejo Medical Center, Mission Viejo, California, stated, "In clinical studies with the Apieron Insight eNO monitor, I found the ability to easily and accurately measure eNO in the physician's office to be a major advancement in my care for patients with persistent asthma."

It is estimated that more than 20 million people in the U.S. suffer from asthma, making it one of the most common and costly of all diseases. In fact, every day in America 40,000 people miss school or work due to asthma and 5,000 people go to the emergency room due to an asthma attack. One-quarter of all emergency room visits are asthma related and asthma is the most common chronic childhood disease.

"We are pleased to offer physicians and their patients a reliable, accurate and affordable asthma measurement and management device," said Rich Lotti, President and CEO of Apieron, Inc. "We believe this product will improve the standard of care for patients with asthma enabling physicians to optimize medical therapy for each patient."

"The availability of simple to use, accurate, and economically feasible eNO measurement devices now enables physicians to intelligently assess and manage the key pathologic feature of asthma, airway inflammation," said Peter B. Boggs, M.D., Clinical Professor of Pediatrics and Medicine, LSU School of Medicine, Shreveport, Louisiana. "Prior to the availability to measure eNO, assessing and managing airway inflammation was, for all practical purposes, little more than a guess! The ability to measure eNO in the physician's office is 'one giant step' in the care of adults and children with asthma."

The Insight eNO system includes a small desktop monitor with an easy-to- read display, trend analysis capabilities and a user-friendly interface. The system uses disposable, single-use sensors to measure nitric oxide accurately and non-invasively in less than a minute. Disposable, single-use breath tubes make it hygienic and convenient for the user to exhale into the device. Patient data can be stored and maintained in unique patient cards for trend analysis or downloaded to a printer for insurers' and patients' files.

About Apieron Inc.

Apieron Inc. is a private, venture-backed medical device company based in Menlo Park, CA that was formed in early 2001 to develop a simple-to-use, non- invasive monitor for the measurement of exhaled nitric oxide (eNO) for the management of asthma. The Apieron biosensor technology platform utilizes a patented technology that allows for the highly sensitive detection of selected analytes like eNO. Apieron is committed to collaborating with physicians and patients to develop innovative medical solutions to improve quality of life and standards of care.

Refer Questions to:

Holly McGarraugh

Apieron, Inc.

650-454-8101


'/>"/>
SOURCE Apieron, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... and biotech research and development (R&D), today announced the establishment of Genedata Limited ... Managing Director Kevin Teburi, a recognized expert in life science informatics. Creating the ...
(Date:2/21/2017)... ... 21, 2017 , ... Creation Technologies, a private company and ... manufacturers (OEMs) , today announced it has received the ‘Highest Overall Customer Rating’ ... its category of electronics manufacturing services (EMS) providers with annual revenues over $500 ...
(Date:2/21/2017)... 21, 2017   Invitae Corporation (NYSE: NVTA), ... announced that members of the company,s management team will ... Care Conference on Monday, March 6, 2017 at approximately ... Boston, Massachusetts . The ... by visiting the investors section of the company,s website ...
(Date:2/20/2017)... 20, 2017 This report analyzes the worldwide markets ... Types: Xylanase, Amylase, Cellulase, and Others. The report provides separate ... Japan , Europe , ... , and Rest of World. Read the ... forecasts are provided for the period 2015 through 2022. Also, ...
Breaking Biology Technology:
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/30/2017)... SAN FRANCISCO , Jan. 30, 2017   ... of the fastest growing genetic information companies, today announced ... 2016 financial results and provide 2017 guidance on Monday, ... a conference call that day at 4:45 p.m. Eastern ... call, Invitae,s management team will briefly review financial results, ...
Breaking Biology News(10 mins):